Skip to content

MDMA: all studies

Page 20 of 345: studies 191 to 200 of 3,446, newest first. Back to the MDMA overview

Research

MDMA-assisted psychotherapy for AUD: Bayesian analysis of WHO drinking risk level and exploratory analysis of drinking behavior and psychosocial functioning at 3 months follow-up.

Alcohol and Alcoholism May 14, 2025 Hannah Thurgur, Ben Sessa, Laurie Higbed et al. 3 citations

Safety and tolerability data from the first open-label feasibility study of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for alcohol use disorder was recently published. This paper presents a Bayesian analysis of the impact of MDMA-assisted psychotherapy on treatment success, defined as 2-level reduction in the World Health Organization (WHO) drinking risk at the 3 months...

Risk communication about high-dose MDMA: Impact of a hypothetical drug alert on future MDMA use.

Drug and Alcohol Review May 1, 2025 Joel Keygan, Breanna Willoughby, Raimondo Bruno et al. 1 citation

Despite high-dose 3,4-methylenedioxymethamphetamine (MDMA) drug alerts being distributed, no research has been conducted as to changes in use in response. This study aimed to determine if: (i) high-dose MDMA drug alerts, and (ii) varied descriptions of dose, effects and actions to reduce harm were associated with intentions to reduce the initial MDMA dose in a hypothetical scenario. Australians...

DOI: 10.1111/dar.14037 (opens in new tab) Full text (opens in new tab) Drug safety alerts MDMA/Ecstasy/Molly Public health interventions Behaviour change +3

Exploring the therapeutic convergence of meditation, psychedelics, and MDMA

Journal of Psychedelic Studies April 17, 2025 Jacob T. Dines

AbstractBackground and aimsPsychedelic and MDMA-assisted psychotherapy are at the forefront of new treatment models for mental illnesses such as PTSD and depression, as well as improving well-being. Mindfulness meditation and loving-kindness meditation have also gained research traction, showing promise for enhancing emotional regulation and psychological well-being. This paper explores the...

DOI: 10.1556/2054.2025.00435 (opens in new tab) Emotional regulation Empathy Reduced distress Mental health +9

Issues in Clinical Trial Design—Lessons From the FDA’s Rejection of MDMA

JAMA Psychiatry April 16, 2025 Samuel T. Wilkinson, Gerard Sanacora 14 citations

This Viewpoint explores potential justifications underlying the US Food and Drug Administration (FDA)’s rejection of methylenedioxymethamphetamine (MDMA) as a treatment for posttraumatic stress disorder, including lack of blinding and issues around the integrity of relevant clinical trials.

DOI: 10.1001/jamapsychiatry.2025.0442 (opens in new tab) MDMA Clinical trial Blinding Clinical research +1

Successful treatment of intractable MDMA adverse reactions using acupuncture and traditional Chinese medicine

Journal of Psychedelic Studies April 2, 2025 Hope Kronman, Alison Locker, Abdi Assadi et al.

Abstract Psychedelic treatments like MDMA can sometimes have side effects which persist despite management with Western medical approaches. In what follows, we present a case study of an individual who suffered from insomnia, anxiety, tinnitus, and more for months following MDMA therapy. Ultimately, her symptoms responded to management within the Traditional Chinese Medicine framework. We...

Comparing Substance Use Consequences between Serotonergic Psychedelics, MDMA, and other Drugs of Abuse Among United States Adults with History of Psychiatric Illness

International Journal of Mental Health and Addiction April 1, 2025 Joshua C. Black, Nicole Schow, Hannah L. Burkett et al. 3 citations

Psychedelic-assisted therapy could transform treating psychiatric illness, but harms from exacerbating substance use disorder (SUD) among adults with psychiatric illness using psychedelics have not been studied. A cross-sectional survey in the US was used to test whether Drug Abuse Screening Test scores (DAST-10, validated instrument predicting SUD) were more severe when psychiatric illnesses...

Zinc Supplementation Reduces ROS Production and Prevents MDMA-Induced Apoptosis in TM3 Leydig Cells via the Inhibition of Pro-Apoptotic Proteins.

Biological Trace Element Research April 1, 2025 Salar Mahmoudi-Nejad, Sina Ahmadi, Mahssa Hassan-Nejhad et al. 4 citations

MDMA can cause serious adverse effects on vital organs such as the heart, brain, and liver. Additionally, MDMA consumption can also potentially cause various endocrine system dysfunctions. The previous study has shown that pre-treatment of zinc can reduce the cytotoxicity of MDMA on the Leydig cell line (TM3). In this study, we investigated the mechanisms involved in the treatment with MDMA on...

A reflection on paradigmatic tensions within the FDA advisory committee for MDMA-assisted therapy.

Journal of Psychopharmacology April 1, 2025 Leor Roseman 12 citations

The recent rejection of 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy by the U.S. Food and Drug Administration (FDA) is a dramatic moment in the re-emergence of psychedelic research. In this perspective, I argue that it represents a case study for paradigmatic tensions within psychopharmacology. The regulatory system is still influenced by a paradigm that sees the therapeutic...

DOI: 10.1177/02698811241309611 (opens in new tab) Full text (opens in new tab) Set and setting Psychedelics hallucinogens Entheogens Psychedelic medicine +7

Social Workers' Attitudes and Beliefs about MDMA-Assisted Therapy for Adolescents with PTSD.

Social Work April 1, 2025 Maha N. Mian, Jordan Horan, Taweh Hunter et al. 1 citation

Given the widespread interest and ongoing study on MDMA-assisted therapy (MDMA-AT) for PTSD, its implications for unique populations-such as adolescents-require further understanding. Social workers will likely play a crucial role in the potential implementation of this intervention, but their perspectives remain unknown. The study includes 222 social workers randomized to read one of two...

MDMA-Assisted Therapy for Post-Traumatic Stress Disorder: Regulatory Challenges and a Path Forward.

CNS Drugs April 1, 2025 Balwinder Singh 6 citations

Trauma is prevalent, with lifetime estimates of traumatic exposure ranging from 70% for a single event to 31% for multiple events. While many recover, a subset develop post-traumatic stress disorder (PTSD), a debilitating condition characterized by distressing memories, avoidance behaviors, hyperarousal, and mood disturbances. The National Comorbidity Survey reports a lifetime PTSD prevalence...